mini review
Dalip Sethi1*, Steve Sampson2,
Monika B Sharma3, Rik Patel4, Mary Ambach5
1Cesca
Therapeutics Inc. Rancho Cordova, USA
2Orthohealing
Center Los Angeles, CA and New York, NY. Assistant Clinical Professor of
Medicine, David Geffen School of Medicine at UCLA, USA
3TotipotentRX
Centre for Cellular Medicine, Subsidiary of Cesca Therapeutics Inc., Gurgaon,
India
4Orthohealing
Center, New York, NY, USA
5Orthohealing Center Los Angeles, CA, Clinical Instructor of Medicine, David Geffen School of Medicine at UCLA, USA
*Corresponding author: Dalip Sethi, Cesca Therapeutics Inc., 2711 Citrus Road, Rancho Cordova, CA 95742, USA. Tel: +19168585163; Fax: +19168585199; Email: dsethi@cescatherapeutics.com
Received Date: 06 April, 2018; Accepted Date: 19 April, 2018; Published Date: 26 April, 2018
1. Abstract
Knee Osteoarthritis (KOA) is a common degenerative joint disease that affects no less than 19% of American adults aged above 45 years. The incidence of Osteoarthritis (OA) is increasing and will continue to do so as the world’s population increases and continues to age. Current treatment strategies for OA include few non-invasive interventions (medications, physical therapy, activity modification and bracing) and invasive therapies (drilling, debridement, osteochondral transplantation, autologous perichondral and periosteal grafts, autologous chondrocyte implantation and arthroplasty). Many of these strategies are focused on pain reduction rather than disease modification or controlling progression. Cell based therapies are emerging as a promising approach to OA treatment and have been shown to reverse the symptoms and pathophysiology of OA. Researchers and clinicians are focusing on the beneficial effects of autologous Bone Marrow Concentrate (aBMC) for the treatment of KOA. The probable repair mechanisms and potential role of cellular and humoral components of aBMC is discussed in this review.
2. Keywords: Bone Marrow Concentrate; Cell Based
Therapy; Knee Osteoarthritis
Copyright and Licensing: This is an Open Access Journal Article Published Under Attribution-Share Alike CC BY-SA: Creative Commons Attribution-Share Alike 4.0 International License. With this license readers can share, distribute, download, even commercially, as long as the original source is properly cited. Read More.